Project Id
|
BITS025F001431
|
Project Detail
|
Project Title
|
Efflux pump inhibitor enhanced antimicrobial peptide-based nanozyme for AMR reversal
|
Senior Supervision Team (BITS)
|
Supervisor name and Title
|
Professor Jayati Ray Dutta
|
School or Department (or company, if applicable)
|
BITS PILANI, HYDERABAD CAMPUS
|
|
|
Email ID
|
jayati@hyderabad.bits-pilani.ac.in
|
URL for more info
|
https://www.bits-pilani.ac.in/hyderabad/prof-jayati-ray-dutta/
|
a) Are you currently supervising a BITS or RMIT HDR student?
|
YES
|
Please comment how many you are supervising
|
8
|
b) Have you supervised an offshore candidate before?
|
NO
|
If no, what support structures do you have in place?
|
|
If yes, please elaborate
|
N
|
Senior Supervision Team (RMIT)
|
Supervisor name and Title
|
A/Prof. Yichao Wang
|
School or Department (or company, if applicable)
|
STEM
|
|
|
Email ID
|
yichao.wang@rmit.edu.au
|
URL for more info
|
https://www.rmit.edu.au/profiles/w/yichao-wang
|
a) Are you currently supervising a BITS or RMIT HDR student?
|
YES
|
Please comment how many you are supervising
|
1
|
b) Have you supervised an offshore candidate before?
|
YES
|
If no, what support structures do you have in place?
|
|
If yes, please elaborate
|
Served as the external supervisor for a Master’s candidate at Qingdao University of Science
adn Technology and collaboratively published a paper in Advanced Functional Materials,
2024, 34, 2407336
|
Other Supervisors (BITS)
|
Supervisor name and Title
|
Ramakrishnan Ganesan
|
School or Department (or company, if applicable)
|
BITS PILANI, HYDERABAD CAMPUS
|
Phone Number (Optional)
|
04066303602
|
Email ID
|
ram.ganesan@hyderabad.bits-pilani.ac.in
|
URL for more info
|
https://universe.bits-pilani.ac.in/hyderabad/ram/Profile
|
Other Supervisors (BITS)
|
Supervisor name and Title
|
Professor Ravi Shukla
|
School or Department (or company, if applicable)
|
STEM
|
Phone Number (Optional)
|
+61 3 9925 22970
|
Email ID
|
ravi.shukla@rmit.edu.au
|
URL for more info
|
https://www.rmit.edu.au/contact/staff-contacts/academic-staff/s/shukla-associate-professor-ravi
|
Field of Research (For Codes)
|
310607 | Nanobiotechnology | 30.00 |
310701 | Bacteriology | 40.00 |
340301 | Inorganic materials (incl. nanomaterials) | 30.00 |
|
Project Description
|
Summary: Antimicrobial resistance (AMR) poses a significant threat to global health, often driven by bacterial efflux pumps that expel antibiotics, reducing their efficacy. This proposal explores a novel strategy to combat AMR by combining an efflux pump inhibitor (EPI) with an antimicrobial peptide-based nanozyme. The nanozyme enhances bacterial killing through catalytic activity while the EPI prevents drug expulsion, ensuring higher intracellular drug retention. This synergistic approach aims to restore antibiotic susceptibility and improve therapeutic outcomes against resistant pathogens. By integrating nanotechnology and biochemical inhibition, this platform offers a promising alternative to conventional antibiotics, potentially overcoming resistance mechanisms and enhancing treatment efficacy. The findings could pave the way for innovative antimicrobial strategies to tackle multidrug-resistant bacterial infections.
Aims:
1) To develop and characterize the antimicrobial peptide-based nanozyme (BITS-9 months)
2) To evaluate the synergistic effect of the Efflux pump inhibitor and nanozyme (RMIT-12 months)
3) To assess the mechanism and potential for AMR reversal (BITS-12 months)
Methodology:
1. Development and characterization of antimicrobial peptide-based nanozyme for stability, catalytic activity and cytotoxicity.
2. Evaluation of the synergistic efficacy of Efflux pump inhibitor and nanozyme and assessing their therapeutic potential in vitro using MIC/MBC assays.
3. Investigation of the mechanism and potential of EPI-AMP based nanozyme for AMR reversal through RT-qPCR, RNA sequencing, passaging and proteomics.
|
Project Deliverable/Outcomes
|
One of the major outcomes of the proposal is the development of a novel antimicrobial platform: A well-characterized antimicrobial peptide-based nanozyme with enhanced catalytic activity, stability, and minimal cytotoxicity.
- With the successful testing through in vitro/in vivo studies, the developed nanozyme will establish the feasibility for future preclinical studies, offering a promising alternative to conventional antibiotics for treating multidrug-resistant infections.
- This approach will also contribute to the scientific community by providing novel insights into efflux pump inhibition and nanozyme-based antimicrobial strategies, paving the way for future translational applications.
- The project shall also contribute to human resource development to the tune of one doctoral candidate and also provide exposure to the undergraduate students with the state-of-the-art research exposure.
- A minimum of three research articles in internationally reputed journals will arise from the project.
- The successful implementation of the proposal is envisioned to result in IPR filing in India and abroad.
- The research can also lead to industry collaboration. The project outcome will be shared with relevant industries through workshops, and also direct meetings.
|
Research Impact Themes
|
BETTER HEALTH OUTCOMES | BIOTECHNOLOGY |
Life sciences | Biotechnology and Bioengineering |
ADVANCED MATERIALS, MANUFACTURING AND FABRICATION | SPECIALISED MATERIALS |
|
Which RMIT Sustainable Development Goal (SDG) does your project align to
|
GOOD HEALTH AND WELLBEING
|
Which RMIT Enabling Impact Platform (EIP) does your project align to
|
BIOMEDICAL AND HEALTH INNOVATION
|
Which RMIT Program code will this project sit under?
|
DR229 (CHEM AND ENVIRO)
|
Student Capabilities and Qualifications
|
Background on Biochemistry/Materials Science/Biological Sciences
|
Cell culture, in vitro/ in vivo culture,microbiological techniques, material design/synthesis
|
Masters by research/ MTech in Microbiology/Materials Science/Biotechnology/Biochemistry
|
Preferred discipline of Student
|
Biotechnology |
Health, Digital Health |
Materials Chemistry |
Nanotechnology, Nanomaterials, Nanomedicine, Nanoscience |
|